The FDA has approved Anzupgo (delgocitinib) cream for the topical treatment of moderate to severe chronic hand eczema in ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

The FDA is recommending that certain products containing 7-hydroxymitragynine be subject to the Controlled Substances Act.

A consensus-based definition for on-treatment remission for patients with plaque psoriasis has been published by the National Psoriasis Foundation.

There was a 1% increase in the number of births and a 1% decrease in the general fertility rate from 2023 to 2024.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients perceived physicians as less competent, trustworthy, and empathetic if they used AI in their practice.

Age at diagnosis, when treated as a continuous variable, appears to impact long-term remission outcomes among patients with JIA.

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...

The recurrence rates of curettage alone are comparable to that of curettage with electrodessication in patients with keratinocyte carcinoma.

The FDA has appointed George Francis Tidmarsh, MD, PhD, to be the director of the Center for Drug Evaluation and Research.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.